Core Committee

 

Kathryn Wagner Kathryn Wagner - Chair of TACT

Professor of Neurology - The Johns Hopkins School of Medicine

Kathryn R. Wagner, M.D., Ph.D. is the Director of the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute and Associate Professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine. She treats patients with muscular dystrophies in a multidisciplinary clinic, addressing the multiple medical and social issues affecting these individuals and families.

More Info

Call +1 443 923 9525

 

Gunnar Buyse Gunnar Buyse

Professor of Pediatrics & Child Neurology - Universite Catholique de Louvain

Gunnar Buyse (MD, PhD) is Professor of Pediatrics and Child Neurology at the University of Leuven (Katholieke Universiteit Leuven), and is deputy clinical chair of Child Neurology at the University Hospitals Leuven. Gunnar Buyse is a Committee Member of the TREAT-NMD Advisory Committee for Therapeutics (TACT).


Call +32 16 34 38 45

 

Didier Caizergues Didier Caizergues - Regulatory Expert

Head of Regulatory Affairs and Quality Assurance - Généthon

Didier is a pharmacist specialised in Regulatory Affairs and also in product development.  Since 2001 he has worked for GENETHON where he has successfully obtained Orphan Drugs designations and Clinical Trial Authorisations for gene therapy products in the field of NMD in several European countries.

More Info

 

Miranda Grounds Miranda Grounds

Professor - University of Western Australia

Miranda has devoted over 30 years of research to better understanding the process of damage and repair of normal skeletal muscle.

 

Petra Kaufmann Petra Kaufmann - Clinical Representative

Director, Division of Clinical Innovation - NCATS

Petra Kaufmann, M.D., M.Sc., is Director of the Office of Clinical Research (OCR). In this capacity, she oversees the clinical research programs funded by the Institute. The OCR fosters clinical research that increases our understanding of the cause, diagnosis, treatment, and prevention of neurological diseases and translates scientific discoveries into improved therapies for people living with neurological diseases worldwide.

More Info

Call +1 301 435 0178

 

Michael  Kelly Michael Kelly

Chief Scientific Officer - CureDuchenne

Dr. Michael Kelly is Chief Scientific Officer of CureDuchenne. Dr. Kelly, a senior pharmaceutical executive, brings more than 25 years of experience in drug discovery and development to the organization. He is responsible for advancing drug development programs and identifying new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.

More Info

 

Annamaria De Luca Annamaria De Luca

Professor of Pharmacology - University of Bari

Annamaria is a pharmacologist specialized in pre-clinical in vivo and ex vivo studies of inherited and acquired neuromuscular disorders. In this general frame, she has a long lasting experience in preclinical research on pharmacological treatments for DMD and collaborates with leading scientists in the field.


Call +38 0805 442245

 

Elizabeth McNally Elizabeth McNally - Clinical Representative

Ward Professor and Director - Northwestern University Feinberg School of Medicine

Elizabeth McNally is Ward Professor and Director at Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.  Professor McNally has led preclinical and clinical research on inherited cardiovascular and neuromuscular diseases. Her expertise in the genetic mechanisms of cardiomyopathies and muscular dystrophies has led to new insight about how heart failure and muscle dysfunction occur.

More Info

 

Tracey Zoetis Tracey Zoetis

Consultant for - SciLucent, LLC.

Tracey Zoetis, M.S. advises sponsors on regulatory and pharmacology/toxicology issues for FDA-regulated products, including pharmaceuticals, biologics, medical devices, and combination products. Her more than 25 years of experience in toxicology has afforded her a broad perspective on varied and interesting product safety issues. She has been employed by two major CROs, the FDA, and both large and small consulting firms.